Trial Profile

A phase IIb/III study of risuteganib (Luminate) for dry age related macular degeneration

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 28 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Sep 2023 According to a AffaMed Therapeutics media release, company announced that China's National Medical Products Administration has approved AffaMed's Clinical Trial Application (CTA) for Risuteganib intravitreal injectable product for the treatment of Intermediate Dry Age-related Macular Degeneration.
12 Apr 2023 According to a AffaMed Therapeutics media release, company has received agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the design of this trial.
21 Sep 2020 According to a Bausch Health Companies media release, this trial is expected to begin within the next 12 months.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com